secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-206396
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OnKure Q1 loss $15.2M; cash $192M; nominates two new PI3Kα inhibitors; halting OKI-219
--------------------------------------------------------------------------------

- Net loss of $15.2M ($1.11 per share) for Q1 2026 vs $15.9M ($1.19 per share) in Q1 2025.
- Cash and cash equivalents $192.1M as of March 31, 2026, including $150M private placement closed on March 31, expected to fund operations into 2029.
- Announced nomination of OKI-355 for vascular anomalies and OKI-345 for breast cancer; IND submissions planned for first half 2027.
- Company will not independently pursue further clinical development of OKI-219; data from PIKture-01 study to be reported by end of 2026.
- R&D expenses $11.7M (down from $13.0M), G&A $3.9M (down from $4.0M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312526206396/0001193125-26-206396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312526206396/okur-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-206396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer